Peptidomimetic-based antibody surrogate for HER2
Acta Pharmaceutica Sinica B
;
(6): 2645-2654, 2021.
Article
in English
| WPRIM
| ID: wpr-888877
ABSTRACT
Inhibition of human epidermal growth factor receptor 2 mediated cell signaling pathway is an important therapeutic strategy for HER2-positive cancers. Although monoclonal antibodies are currently used as marketed drugs, their large molecular weight, high cost of production and susceptibility to proteolysis could be a hurdle for long-term application. In this study, we reported a strategy for the development of artificial antibody based on
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Acta Pharmaceutica Sinica B
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS